Kornimate/medical-research-clean huggingface dataset:
improvement in acoustic voice characteristics in functional dysphonia after therapy

Conditions: Functional Voice Disorder

Summary: in a retrospective analysis of already existing clinical assessment data from patients with functional voice disorders the following aspects will be sampled, encoded and analysed: outcomes pre and post treatment of 1. subjective voice symptoms measured by voice handicap index (vhi-9i), 2. perceptual voice symptoms according to grading-roughness-breathiness-asthenia-strain scale (grbas scale), 3. instrumental acoustic analysis parameters jitter (%), speaking voice profile: mean and range of speaking pitch and intensity, max. intensity and mean pitch of calling voice, singing voice: min./max. and range of pitch and intensity, maximum phonation time, dysphonia severity index (dsi).


Eligibility criteria:
inclusion criteria: * informed consent; patients 20 to 70 years with functional voice disorder; -diagnostics and voice therapy at university hospital zurich; * full pre- and post treatment voice assessment (videostroboscopy, subjective self- assessment, instrumental acoustic and perceptual analysis). exclusion criteria: * known neurologic and psychiatric disease, * hearing disorder, * surgery of the head and neck area or intubation (for any reason) in last 18 months.
physiological and qol benefits of qi-gong in post-acute sequelae of covid-19

Conditions: PASC Post Acute Sequelae of COVID 19

Summary: the goal of this clinical trial is to determine whether qi-gong can improve physiological function and quality of life (qol) in individuals with post-acute sequelae of sars-cov-2 infection (pasc). study objectives: to assess whether qi-gong improves physiological function in individuals with pasc. to evaluate whether qi-gong enhances quality of life in individuals with pasc. study design: if a comparison group is included, researchers will compare qi-gong with standard care to assess its effectiveness. participant involvement: practice qi-gong three times per week for three months. record physiological data monthly.


Eligibility criteria:
inclusion criteria: * pasc * above 20 y/o exclusion criteria: * those who cannot cooperate * severe schizophrenia
a trial to investigate the accuracy of a wearable device in collecting data related to perimenopausal symptoms in women

Conditions: Perimenopause; Perimenopausal Depression; Perimenopausal Insomnia; Perimenopausal Women; Menopausal Depression; Menopausal Hot Flashes; Menopausal and Postmenopausal Disorders; Menopausal Vasomotor Symptoms

Summary: the goal of this observational study is to investigate the accuracy of the device in characterizing perimenopausal and menopausal symptoms including vasomotor symptoms, anxiety, sleep quality compared to self-reported symptoms via an app. the main question it aims to answer is: what is the accuracy of the developed algorithm from the investigational device compared to daily self-report via an app in characterizing perimenopausal symptoms? participants will be asked to wear indentifyher's wearable non-invasive sensor and complete a daily electronic diary and questionnaires on stress, anxiety, and sleep.


Eligibility criteria:
inclusion criteria: 1. females between 35-55 years of age, inclusive 2. self-reported perimenopausal women experiencing hot flushes or night sweats 3. individuals of child-bearing potential must confirm they are not pregnant, do not plan to become pregnant, and agree to use a medically approved method of birth control for the duration of the study. acceptable methods of birth control include: * double-barrier method * intrauterine devices * non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) * vasectomy of partner at least 6 months prior to screening * abstinence 4. agrees to maintain current lifestyle as much as possible throughout the study, including diet, exercise, supplements/medications, and sleep 5. provided voluntary and informed consent to participate in the study 6. generally healthy as determined by medical history with no unstable diagnosed medical conditions exclusion criteria: 1. allergy or sensitivity to adhesive used for wearing the investigational device 2. self-reported use of a pacemaker 3. self-reported unstable diagnosed anxiety disorder 4. self-reported sleep disorder requiring medical treatment 5. self-reported skin conditions or sensitive skin around the area of application 6. self-reported surgery in the past three months or individuals who have planned surgery during the course of the study 7. alcohol intake average of ˃1 standard drink per day 8. alcohol or drug abuse within the last 12 months that has required treatment 9. current use of prescribed and/or over-the-counter (otc) medications/supplements that may impact data recorded by the investigational device (see section 7.3) 10. participation in other clinical research studies 30 days prior to screening 11. individuals who are unable to give informed consent 12. any other condition or lifestyle factor, that may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

Keywords: menopause perimenopause vasomotor symptoms hot flashes identifyher peri perimenopausal symptoms
minimally invasive treatment of hypertensive basal ganglia hemorrhage by transfrontal keyhole neuroendoscopy

Conditions: Basal Ganglia Hemorrhage

Summary: to compare the prognosis of patients with hypertensive intracerebral hemorrhage treated by two different surgical methods, and to clarify the therapeutic effect of minimally invasive surgery, so as to find a better surgical method that can reduce surgical trauma and mortality and improve the prognosis of patients

in this study, a cohort observation method was adopted to observe a total of 52 patients who underwent two surgical procedures, namely, removal of hematoma in basal ganglo-region by keyhole neuroendoscopy under frontal ultrasound guidance and removal of hematoma by craniotomy microsurgery. they were divided into the endoscopic surgery group and the microsurgery group. in the endoscopic surgery group, 26 patients underwent removal of hematoma in basal ganglo-region by keyhole neuroendoscopy under frontal ultrasound guidance.in the microsurgery group, 26 cases were treated with craniotomy microsurgery for hematoma removal. the clearance rate of surgical hematoma, surgical safety, gcs score, gos score, nerve fiber injury and postoperative complications were observed in the two groups 1 week, 1 month and 3 months after surgery.to observe and analyze whether endoscopic surgery group has advantages in improving hematoma clearance rate and efficacy

Eligibility criteria:
inclusion criteria: * ct scan was used to diagnose cerebral hemorrhage in basal ganglia region. the amount of bleeding was 30-50ml, and no cerebral hernia was formed. * age between 30 and 70 * the onset is longer than 24 hours and less than 72 hours. * informed consent of the patient and/or their relative. exclusion criteria: * brain injury, hemorrhage caused by intracranial aneurysm or cerebral arteriovenous malformation. * coagulation dysfunction * insufficiency of vital organs of heart, liver, kidney or lung * previous history of stroke with functional loss * intracranial or systemic infection * poor blood pressure control

Keywords: hypertensive basal ganglia hemorrhage transfrontal keyhole neuroendoscopic technique ultrasonic positioning
effectiveness and cost-effectiveness of a pre-emptive genotyping strategy in patients receiving tacrolimus

Conditions: Kidney Disease, Chronic; Transplant Recipient (Kidney); Immunosuppression

Summary: this is a phase iv multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective, cost-effective, and feasible within the spanish national health system when compared to the current standard of care. this trial is nested within the ipharmgx master protocol.

this is a nation-wide, multicentre, randomised, controlled, and adaptive phase iv clinical trial that aims to assess the effectiveness and cost-effective of pre-emptive pharmacogenetic testing strategies, including those impacted by genetic variants associated with adverse drug reactions (adrs) or limited efficacy. the clinical trials will evaluate the effective and cost-effective of pre-emptive genotyping by defining a drug-gene-endpoint triad. study subjects will be pre-emptively genotyped and, if found to have an actionable gene variant, randomly allocated to either a test group where guideline-based treatment modifications will be initiated or a control group that will be managed according to healthcare provider standard of care (soc). subsequently, subjects will be prospectively followed at prespecified timepoints. detailed information on drug-gene-endpoint triads, allocation schemes, and follow-up visits will be provided in each of the subprotocols. a data monitoring committee (dmc), composed of physician experts, will be appointed for each nested trial to review the data on an ongoing basis, ensuring the safety of participants and scientific validity of the study.

Eligibility criteria:
inclusion criteria: 1. participants must be willing and able to provide written informed consent prior the initiation of any study procedures. 2. subject or their legally authorized representative has voluntarily signed the informed consent document. 3. participant is on the waiting list for a kidney transplant. 4. subject is able and willing to take part and be followed-up for the majority of the study duration, and adhere to the procedures specified in this protocol. 5. subjects must be naïve to any genotyping test of the following genes: cyp3a5. exclusion criteria: 1. known hypersensitivity/allergy reaction to tacrolimus or any of the excipients. 2. history of renal, heart, and/or liver transplant. 3. history or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere in a relevant manner with the absorption, distribution, metabolism, or excretion of the study treatment, except for renal disease. 4. any condition or situation precluding or interfering the compliance with the protocol. 5. any condition at medical discretion for which renal transplantation and/or study treatment should not be received.

Keywords: tacrolimus kidney transplant cost-effectiveness pharmacogenetic phase iv clinical trial
progesterone to enhance the efficacy and success of expectantly managed preterm severe/superimposed preeclampsia

Conditions: Pregnancy

Summary: the purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 ohpc) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.

the obgyn house and attending staff on duty caring for the patient will determine appropriateness for study inclusion. the treating physician will then immediately contact the mfm fellow on call and research division personnel to facilitate the initiation of study procedures, including the consent process and baseline blood tests. once enrolled with informed consent, the participant will receive 17 ohpc, 250mg im to be given at admission and every 7 days thereafter. blood sampling of approximately 1-2 teaspoons each will be collected at baseline immediately prior to administration of 17 ohpc, then 24 hours (+-2hrs). after the first 24 hours, blood samples will be collected every 72 hrs until delivery and again 24hrs (+- 2hrs) after delivery. placentas will be collected at delivery and the investigators will also collect information of the mother and newborn while in the hospital and until discharge including de-identified routine ultrasound.

Eligibility criteria:
inclusion criteria: * ummc antepartum patients with preterm pe between 23 0/7ths and 34 0/7ths weeks gestation when initially evaluated * willing and able to understand study procedures and to provide informed consent exclusion criteria: * \>33 weeks gestational age or \<23 weeks gestation * maternal compromise requiring emergent delivery (ongoing placental abruption, dic, pulmonary edema). * fetal compromise requiring emergent delivery (fetal bradycardia, recurrent late fetal heart rate decelerations, minimal to absent fetal heart rate variability). * parameters according to current practice guidelines that exclude a patient from expectant management include the following: * preterm premature rupture of membranes (pprom) \> 34 weeks gestation; * platelet count \< 100,000/microliter (thrombocytopenia) with evidence of hellp syndrome; * persistently abnormal hepatic enzyme concentrations (twice or more upper normal values); * severe fetal growth restriction (ultrasound-estimated fetal weight less than fifth percentile); * severe oligohydramnios (afi \< 5cm) * reversal of end diastolic flow(redf) in umbilical artery doppler testing; * recurrent (\> 2 readings \> 30 minutes apart) severe hypertension despite antihypertensive therapy; * eclampsia; * pulmonary edema; * abruption placentae; * nonreassuring fetal status during daily testing (biophysical profile \<4/10 and/or recurrent variable or late decelerations); * iufd
biomarkers in perioperative management

Conditions: Postoperative Complications; Quality of Life; Death

Summary: rationale: the rate of postoperative complications after high-risk surgery remains high despite recent advances in perioperative management. there is a lack of objective and reliable information that can be used for risk stratification and to guide treatment decisions. objective: to describe the perioperative biomarker response in surgical patients with and without a postoperative complication and construct a preoperative and postoperative prediction model for postoperative complications. to systematically collect perioperative blood samples and clinical data in high-risk surgical patients for the development en analysis of biomarkers. study design: multicenter, prospective, observational study. study population: 4819 patients undergoing elective cardiac, colorectal, vascular and lung surgery. intervention (if applicable): not applicable. main study parameters/endpoints: main study parameters are levels of pct, crphs, il-6, gdf-15, sflt, nt-probnp, ctnths, cysc and ngal. main study endpoint is the occurrence of a major postoperative complication which is defined as a surgical site infection, pneumonia, sepsis, acute kidney injury, major adverse cardiovascular events or death within 30 days of surgery. nature and extent of the burden and risks associated with participation, benefit and group relatedness: in each patient five blood samples will be drawn for analysis. most of the blood samples are drawn simultaneously with routine perioperative laboratory testing, which is common in this study population. in case a patient is admitted to the intensive care unit blood samples will be collected using an arterial line. there are no direct risks or benefits for patients included in the study.


Eligibility criteria:
inclusion criteria: * cardiac surgery (isolated coronary artery bypass grafting or combined with single valve surgery, isolated single valve surgery) * gastrointestinal surgery (colorectal, pancreatic, gastric surgery). * vascular surgery (open and endovascular aortic surgery, peripheral vascular surgery) * lung surgery (pneumonectomy,(bi)(sleeve)lobectomy or segmentectomy) exclusion criteria: * age \< 18 years * pregnancy * emergent surgery * no informed consent
a comparison of the effects on cardiovascular risk factors of korean and american dietary profiles

Conditions: Hypercholesterolemia

Summary: the primary aim of this study is to compare, in a group of at-risk individuals, the role of three dietary patterns on indices of cardiovascular disease (cvd) risk: a) the recommended korean pattern; b) the typical american diet, based on national dietary intake surveys; and c) the 2010 dga diet pattern. a secondary aim will be to assess the effects of each diet on intestinal microbiota and on inflammatory biomarkers.


Eligibility criteria:
inclusion criteria: * non asian-american men and women between the ages of 25-65 years * body mass index (bmi) ≥ 25 and ≤ 38 kg/m2 * fasting ldl-cholesterol ≥ 130 mg/dl * willingness and ability to make scheduled appointments at clinical site as required by study protocol exclusion criteria: * major aversions to korean foods * known food allergies that would interfere with study protocol * use of cholesterol-lowering medication or dietary supplements * use of blood pressure medications * use of prebiotics or probiotics in the last 3 months * received medication for bacterial infection (antibiotic) in the last 3 months * regular use of fiber supplements or laxatives * conditions requiring ongoing medical care and/or medication, including kidney, liver, gastrointestinal or endocrine disorders. * regular tobacco use within 6 months prior to the start of the study * history of eating disorders or other dietary patterns which are not consistent with the dietary intervention (e.g., vegetarians, very low fat diets, high protein diets) * voluntary or involuntary weight loss of 10% of body weight within the last 12 months * self-report of alcohol or substance abuse within the past 12 months * donated blood during the 8 week period prior to the study * other medical, psychiatric, or behavioral factors that in the judgment of the principal investigator may interfere with study anticipation or the ability to follow the intervention protocol
inflammation as a predictor in cardioversion of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the laboratory test, c-reactive protein (crp), has become well established as a marker of inflammation. recently a high crp level (indicating an increase in inflammation) was identified as a risk factor for atrial fibrillation. we are conducting this study with patients such as yourself with atrial fibrillation who are planning to undergo cardioversion to determine what sort of relationship exists between crp levels and atrial fibrillation. we will then look at success rates of converting atrial fibrillation to normal sinus rhythm, compared to patients' crp levels.


Eligibility criteria:
inclusion criteria * atrial fibrillation patients referred for dc cardioversion * on stable medical therapy exclusion criteria * known chronic inflammatory states such as infections, rheumatoid arthritis or known vasculitides. * patients having undergone recent surgery or who are on steroid therapy for any reason will be excluded.

Keywords: hscrp
comparison of acupuncture and fluoxetine on quality of life in menopausal women

Conditions: Hot Flash; Quality of Life

Summary: the purpose of this study is to comparison the effect of acupuncture and fluoxetine on improvement quality of life among menopausal women.

this clinical trial is designed in two arm include acupuncture and fluoxetine group to evaluate the effect of these intervention on improvement quality of life among menopausal women.

Eligibility criteria:
inclusion criteria: * last menstrual cycle 12 months ago * natural menopause * 4 episodes of hot flash daily * follicle stimulating hormone (fsh)= 30-110 iu/l , e2\<18pg/ml * thyroid-stimulating hormone(tsh)= 0.4-4/0 iu/ml * no using of herbal agent for treatment of hot flash * having score in beck depression inventory\<10 * no existence of any medical problems and using drugs exclusion criteria: * not completing all acupuncture sessions * not completing fluoxetine admission * withdraw the study

Keywords: hot flash acupuncture fluoxetine quality of life
mk3207 for treatment of acute migraines (3207-005)

Conditions: Migraine

Summary: the purpose of the study is to demonstrate the effectiveness and appropriate dosage level of mk3207 in the treatment of acute migraine.


Eligibility criteria:
inclusion criteria: * men and women from 18 to 65 years of age * 1+ year history of migraine that typically last from 4 to 72 hours if untreated * had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months * not pregnant or planning to become pregnant in next 6 months exclusion criteria: * pregnant or breast-feeding, or planning to become pregnant in next 6 months * cannot distinguish migraine attacks from tension type headaches * migraines are mild or resolve without medication in less than 2 hours * more than 15 headache-days per month or have taken medication on more than 10 days per month in the last 3 months * basilar type or hemiplegic migraine headaches * more than 50 years old when migraines began * history of cardiovascular disorder within last 6 months
ric allo-hsct vs. venetoclax-based consolidation in elderly aml patients after first cr

Conditions: Acute Myeloid Leukemia

Summary: elderly patients with acute myeloid leukemia (aml) often face unfavorable prognostic factors such as multiple comorbidities, adverse cytogenetic profiles, and pre-existing hematological disorders. the long-term survival rate remains very low, with a 5-year survival rate of only 5% to 10%. the introduction of the bcl-2 inhibitor venetoclax (ven) has improved the induction remission rates in elderly patients. however, the question of whether to use chemotherapy maintenance or proceed with allogeneic hematopoietic stem cell transplantation (allo-hsct) for post-remission consolidation therapy remains unclear due to the lack of prospective controlled studies. therefore, our center plans to conduct a prospective, open-label, two-arm, non-randomized, single-center study to further explore the optimal consolidation treatment strategy for elderly aml patients at intermediate and high risk following induction complete remission (cr).


Eligibility criteria:
inclusion criteria: * diagnosed with aml according to the 2022 who diagnostic criteria; * age 60-75 years; * intermediate to high-risk aml according to the eln criteria, aml with myelodysplasia-related changes (aml-mrc) or therapy-related aml (t-aml), or core-binding factor aml (cbf-aml) with d816 kit mutation; or newly diagnosed hypercellular leukemia (wbc ≥ 10×10\^9/l); * achieved cr or cr with incomplete hematologic recovery (cri) after one to two courses of induction chemotherapy; * have a matched related, haploidentical, or mismatched unrelated hematopoietic stem cell donor; * eastern cooperative oncology group (ecog) performance status score of 0-2; creatinine clearance ≥ 60 ml/min (calculated using the cockcroft-gault formula); * aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤ 3× the upper limit of normal (uln), and total bilirubin ≤ 2× uln; * echocardiography (echo) showing left ventricular ejection fraction (lvef) ≥ 50%; expected survival \> 8 weeks; * voluntarily signed the informed consent form and can understand and comply with the study's requirements. exclusion criteria: * currently has clinically active cardiovascular disease, such as uncontrolled arrhythmias, uncontrolled hypertension, congestive heart failure, any class 3 or 4 heart disease according to the new york heart association (nyha) functional classification, or a history of myocardial infarction within 3 months before screening; * other severe diseases that may limit the patient's participation in this trial (e.g., severe infection, renal failure); * known human immunodeficiency virus (hiv) infection or severe viral hepatitis not controlled by medication; * pregnant or breastfeeding women; * unable to understand, comply with the study protocol, or unable to sign the informed consent form.

Keywords: elderly aml venetoclax allo-hsct